Overview: This clinical trial will study how safe and effective a new drug is for children and adolescents with certain growth conditions. Participants will be male and female children between the ages of 2 and 18.
Overview: The trial is designed to evaluate the safety of CNP-103 and explore if it may help protect insulin-producing beta cells that support better blood sugar control. Participants will be 12 - 35 years old, male or female, and diagnosed with Stage 3 T1D within the last 6 months.
Overview: This study evaluates the safety and effectiveness of a medication aiming to preserve function of insulin producing cells. Participants will be ages 1 to 25, male or female.
Overview: This study aims to help us learn about growth in children with idiopathic short stature and does not involve any study drugs or treatments.
Fill out the form below an we will let you know when a study becomes available that you may be interested in:
